Cadila develops a drug, which can prevent cardiac diseases

pharma major Cadila Pharmaceuticals Ltd (CPL) has developed a medicine Polycap, which will have far reaching repercussions in
preventing cardiovascular diseases in the world, claimed company officials.
The drug developed by CPL will soon be available in the market in the country and CPL will also launch it abroad after proper registrations, CPL's Indravadan Modi said.
Sharing the details with media of the newly developed tablet, CPL chairman Indravadan Modi and senior scientists said that research of Polycap revealed that the tablet reduced the risk of coronary heart disease by 62 per cent and stroke by 4 per cent.
According to The Indian Polycap study published in the latest edition of the Lancet, Polycap can bring down the risk of coronary heart disease by 62 per cent and stroke by 42 per cent.
The study mentioned that cardiovascular diseases and predominantly heart disease and stroke account for around 30 per cent deaths in the world.
"A healthy person, who is at rick of heart diseases, would ordinarily need to take 5-6 pills of different medications daily. While Polycaop has been developed with a combination of five constituents, three blood pressure lowering drugs with statin, aspirin and folic acid," he said, explaining the technicalities of the drug.